Phase 3 TRIUMPH readouts show dose-dependent mean weight loss up to ~30% at 104 weeks in obesity and ~21% in T2D, with ...
The cereblon E3 ligase modulator, or CELMoD, also received a breakthrough therapy designation from the FDA. The FDA has granted an accelerated approval to the regimen ...
Effective October 13, 2026, federal financial participation is barred for specified pharmacologic and surgical interventions for Medicaid beneficiaries under 18 and CHIP enrollees under 19. CMS ...
Forecasted cost growth was highest in fully insured arrangements, consistent with constrained data rights; only about 60% felt able to audit full claims files. Employers with complete claims data ...
A narrative review found obesity independently worsens psoriasis severity and blunts response to fixed-dose biologics, ...
The Women’s Health Initiative, launched in 1991 across 40 centers with >161,000 participants, materially influenced practice ...
The disparity in outcomes between pediatric and young adult patients with ALL is multifactorial, explained Emily K. Curran, MD.
Katherine Wilemon, Family Heart Foundation, described the biggest unmet need when it comes to public awareness of Lp(a) and ...
A large UK cohort study found atopic dermatitis raises the risk of shingles by 28%, with the steepest risk in severe disease ...
The FDA approved Moderna’s Biologics License Application (BLA) for its mRNA-based flu vaccine, mRNA-1010 (mFlusiva; Moderna), ...
Disease-modifying antirheumatic drug (DMARD) and tumor necrosis factor (TNF) cycling is a real and well-documented problem in ...
Presidential directive reinstates a stayed 11-disease schedule outside ACIP, potentially sidestepping ongoing litigation while compressing review into an HHS-led 90-day planning process. Core ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results